CORPORATE EXCELLENCE CATEGORY
Gwo Xi Stem Cell Applied Technology Co., Ltd.
Healthcare, Pharmaceutical & Biotechnology Industry
www.gwoxi.com.tw
Information about the Company
Gwo Xi Stem Cell Applied Technology Co., Ltd. (Gwo Xi), a Taiwanheadquartered biopharmaceutical company was established in 2004. Gwo Xi applies stem cell technology to innovate new applications in regenerative and preventive medicines, set up health-examination platforms and develop innovative stem cell drugs.Gwo Xi established its first base, Stem Cell Research and Development Centre in Taiwan. Through self-developed platforms, Gwo Xi rolled out an entirely new generation medicine, gene regulated cell therapies. Utilising these cell therapies to replace damaged or degenerated tissues brings the potential to restore or regenerate lost functions. A number of these new stem cell drugs are currently undergoing human clinical trials.
Besides new drug development, Gwo Xi also manufactures drugs. Anticipating robust demand for stem cell medicine, Gwo Xi has build an advanced PIC/S GMP factory in Taiwan. The factory integrates an intelligent manufacturing and cryopreservation system and targets an output of 100,000 vials of drugs per year using the cutting-edge technology.
Corporate Culture & Company Activities
Gwo Xi is also committed Corporate Social Responsibility principles, including improving corporate governance, developing regional culture, promoting education and social care.Gwo Xi considers employee training as a way to drive innovation and sustainable development. In 2020, over 855 training hours were offered to employees, with each employee receiving an average of 16 training hours on learning new technology skills, regulatory compliance, occupational safety, as well as physical and mental health.
In the quest for development, Gwo Xi not only pursues business growth, but also attaches importance to social care. The company participates in social care activities each year, helping patients with life-threatening conditions and helping patients to regain their ability to work.
Innovation, Outstanding, Responsibility.
Achievements and Impact
Gwo Xi has achieved several significant accomplishments which included establishing the Core Technology: Nigiro-Med® modular design cell manufacturing platform and promoting new stem cell drug into clinical trials.Bringing the concept of the semiconductor manufacturing process into the field of stem cell manufacturing, Gwo Xi established the Production Technology Platform of Pharmaceutical Grade ADSC Products (a patented-manufacturing platform), which includes isolation, purification, expansion, storage, filling, package and transport of human stem cells. Gwo Xi has developed the innovative technology platform for the production of pharmaceutical-grade fat stem cell medicine through Industry-university cooperation. The processes become “Modularisation” and modular design increases the manufacturing capacities by more than 5 times. This progression means that stem cell could start volume production and successfully move into the business stage.
In order to achieve process standardisation, innovation and compliance with regulatory requirements, Gwo Xi has been actively investing in the development of the new stem cell drug of many unmet medical diseases since 2010. The company has actively established core technologies through cooperation with industry, official, university and medical fraternity. Three new stem cell drugs were successfully promoted to clinical trials by June 2020 including GXHPC1 (Indication: liver cirrhosis), GXNPC1 (Indication: chronic stroke) and GXCPC1 (Indication: osteoarthritis).
Future Direction
With a dedicated R&D team, Gwo Xi is committed to develop stem cell therapy technologies and capabilities that have potential for commercial applications and meet medical needs. In the longerterm, the company’s goal is to integrate its resources to build a stem cell specialist hospital.COMPANY MILESTONES
